Vanderkerken K - Search Results

1

An improved harvest and in vitro expansion protocol for murine bone marrow-derived mesenchymal stem cells.

Xu S, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. Xu S, et al. Among authors: vanderkerken k. J Biomed Biotechnol. 2010;2010:105940. doi: 10.1155/2010/105940. Epub 2010 Dec 20. J Biomed Biotechnol. 2010. PMID: 21197440 Free PMC article.

2

Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells.

Vanderkerken K, Vande Broek I, Eizirik DL, Van Valckenborgh E, Asosingh K, Van Riet I, Van Camp B. Vanderkerken K, et al. Clin Exp Metastasis. 2002;19(1):87-90. doi: 10.1023/a:1013891205989. Clin Exp Metastasis. 2002. PMID: 11918087

3

Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis.

Asosingh K, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. Asosingh K, et al. Among authors: vanderkerken k. Blood. 2003 Apr 15;101(8):3136-41. doi: 10.1182/blood-2002-10-3000. Epub 2002 Dec 12. Blood. 2003. PMID: 12480692 Free article.

4

The F-actin content of multiple myeloma cells as a measure of their migration.

Menu E, Braet F, Timmers M, Van Riet I, Van Camp B, Vanderkerken K. Menu E, et al. Among authors: vanderkerken k. Ann N Y Acad Sci. 2002 Nov;973:124-36. doi: 10.1111/j.1749-6632.2002.tb04620.x. Ann N Y Acad Sci. 2002. PMID: 12485848

5

Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.

Asosingh K, Menu E, Van Valckenborgh E, Vande Broek I, Van Riet I, Van Camp B, Vanderkerken K. Asosingh K, et al. Among authors: vanderkerken k. Clin Exp Metastasis. 2002;19(7):583-91. doi: 10.1023/a:1020987830132. Clin Exp Metastasis. 2002. PMID: 12498387

6

Selective in vivo growth of lymphocyte function- associated antigen-1-positive murine myeloma cells. Involvement of function-associated antigen-1-mediated homotypic cell-cell adhesion.

Asosingh K, Vankerkhove V, Van Riet I, Van Camp B, Vanderkerken K. Asosingh K, et al. Among authors: vanderkerken k. Exp Hematol. 2003 Jan;31(1):48-55. doi: 10.1016/s0301-472x(02)00970-0. Exp Hematol. 2003. PMID: 12543106 Free article.

7

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B, Croucher P. Vanderkerken K, et al. Cancer Res. 2003 Jan 15;63(2):287-9. Cancer Res. 2003. PMID: 12543775

8

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.

Croucher PI, Shipman CM, Van Camp B, Vanderkerken K. Croucher PI, et al. Among authors: vanderkerken k. Cancer. 2003 Feb 1;97(3 Suppl):818-24. doi: 10.1002/cncr.11125. Cancer. 2003. PMID: 12548581 Free article.

9

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B, Vanderkerken K. Croucher PI, et al. Among authors: vanderkerken k. J Bone Miner Res. 2003 Mar;18(3):482-92. doi: 10.1359/jbmr.2003.18.3.482. J Bone Miner Res. 2003. PMID: 12619933 Free article.

10

Delayed in vivo disease progression is associated with high proportions of CD45+ myeloma cells in the 5T2MM murine model.

Asosingh K, Willems A, Van Riet I, Van Camp B, Vanderkerken K. Asosingh K, et al. Among authors: vanderkerken k. Cancer Res. 2003 Jun 15;63(12):3019-20. Cancer Res. 2003. PMID: 12810619

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

194 results

Search Page